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Abstract
Background Chronic lymphoedematous limbs have an increased propensity for infections and primary or
secondary malignant tumours. It has been attributed to suppressed delayed-type hypersensitivity measured in
lymphoedemas related to Stewart–Treves syndrome, Kaposi’s sarcoma or breast cancer treatment. Cell-mediated
immunity is an effective defence mechanism against bacteria, fungi, viruses and tumour cells.
Objective We aimed to examine whether decongestive lymphoedema therapy could improve cell-mediated
immunity in breast cancer treatment-related lymphoedema (BCRL).
Methods Eight women with unilateral BCRL were included in this study. At baseline, tuberculin skin test (TST) was
performed on the volar surfaces of the forearms of the affected and non-affected sides using 0.5, 1 and 5 tuberculin
units in the form of three consecutive injections with 3-cm spaces in-between, and arm volumes were measured
using the Kuhnke’s disc model. Decongestive lymphatic therapy was given to swollen arms in 10 consecutive
working days. At the end of intensive decongestion, TST on affected side and bilateral volumetry were repeated.
Results Baseline test using undiluted (5 units) and fivefold diluted (1 unit) tuberculin solutions has shown significant
differences (P < 0.05) between the mean sizes (11.81 ± 2.32 and 7.75 ± 1.92; 7.12 ± 1.12 and 5.12 ± 0.91
respectively) in favour to healthy arms. Post therapeutically, the mean sizes were significantly increased (P < 0.05) in
the dilutions of 1 : 1 and 1 : 5 (7.75 ± 1.92 and 10.56 ± 1.23 mm, 5.12 ± 0.91 and 5.93 ± 1.74 mm respectively).
Conclusion Significant increase in TST sizes suggests that decongestive lymphatic therapy is able to partially
restore impaired cellular immune function in BCRL.






The lymphatic system plays multiple roles in the maintenance
of homeostasis: fluid and protein balance of the interstitium,
fat transport, immune surveillance and waste scavenging. In case
of lymph stasis these functions are perturbed, and among others
lymphoedema becomes a local site of altered immuncompetence.
It was supported by a study demonstrating impaired dendritic
cell and lymphocyte trafficking in 14 patients with lymphoedema
of mechanical causes.1 Lymphoedematous limb has a high propen-
sity for bacterial, fungal and viral infections, and is also at risk
for the onset of malignant tumours and their metastases.2,3 As
Ruocco et al. and Mallon et al. have shown in their clinical stud-
ies in lymphoedemas with Stewart–Treves syndrome,4 Kaposi’s
sarcoma (KS)5–7 or breast cancer treatment,8 such susceptibility to
malignancy seems to have close relationship with an altered
cell-mediated immunity measured with standard antigens and
dinitrochlorobenzene (DNCB). Clinical observations and retro-
spective analyses well reported that proper oedema control
might be able to reduce the frequency of erysipelas, which might
reflect the improvement of defence mechanism against infectious
bacteria.9
Therefore, we aimed to measure the cell-mediated immunity
with tuberculin skin test (TST), prior and subsequent to deconges-
tive lymphatic therapy10 (DLT)-based standard care of breast
cancer treatment-related secondary lymphoedema (BCRL). As
control we used contralateral healthy arm for TST. Because of
the concern on possible DNCB genotoxicity,11 we decided to use
purified protein derivative (PPD) of Mycobacterium tuberculosis,
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which has been known to serve as a reliable model for delayed
hypersensitivity with no biohazard activity.
Methods
Eight women [mean age: 58 years (range: 51–77 years)] with
BCRL [mean duration: 27.5 months (range: 12–52 months)] were
included in our prospective study after a written informed
consent. This study was approved by the local Ethical Committee
of the University of Szeged.
All patients had previously undergone excisional breast surgery,
axillary block dissection and radiotherapy. Seven of eight patients
also received postoperative chemotherapy. All participants were
proved to be tumour-free in complete cancer screening conducted
within the last 3 months.
Limb volumes of both affected (mean value: 3463 cm3 in range
2650–4230 cm3) and healthy arms (mean value: 2998.75 cm3 in
range 2318–3830 cm3) were determined using Kuhnke’s method.12
Mean oedema volume (volume difference between affected and
non-affected arm) measured as the baseline was 464.25 cm3
(range: 197–798 cm3).
TST was performed on the volar surfaces of both forearms with
three consecutive injections of 0.5, 1 and 5 international units
(IU) of 0.1 mL PPD solution (Teva, Debrecen, Hungary) prior to
DLT. Serial injections were administered with 3-cm spaces among
each inoculation to avoid a false positivity.
DLT was given daily for 10 consecutive weekdays, and
comprised manual lymph drainage (MLD) of Vodder’s method
performed along the neck, breast, abdomen and then affected arm
using light pressure (20–30 mmHg) for 60 min, followed by skin
moisturization and multilayered (50% overlap) and multicom-
ponent short-stretch bandaging with appropriate padding.13 The
pressure of the bandage system was set to the values between 30
and 39 mmHg in vertical position with dangling arm.
TST was repeated exclusively in lymphoedematous forearms
after completing the full course of the DLT. The reading of the
test results was regularly performed by two independent examin-
ers for 72 h with measurement of the size of induration given
in millimetres,14 thus each final value represents the mean of two
single measures.
To rule out boosting effect (increased test reactions), two-step
TST was performed using 5, 1 and 0.5 tuberculin units on one
selected forearm of eight healthy individuals (mean age 32, range:
24–52 years) on days 1 and 16. No significant difference was mea-
sured in the diameters of inflammatory reactions of the identical
dilutions (P > 0.05) revealing no false conversions in repeated
course of TST.
Statistical analysis
Statistical analyses were performed using the Student’s t-tests for
paired samples and differences were accepted as significant when
P < 0.05. Statistica 9.1 software (Stat Soft, Tulsa, OK, USA) was
used for data analysis.
Results
As shown in Table 1, baseline test using undiluted (5 units) and
fivefold diluted (1 unit) tuberculin solutions has shown significant
differences (P < 0.05) to be measured between the mean diame-
ters of reactions (11.81 ± 2.32 and 7.75 ± 1.92; 7.12 ± 1.12 and
5.12 ± 0.91 respectively) in favour to healthy limbs. At the end
of DLT course, the mean diameters of the reactions were signifi-
cantly increased (P < 0.05) in the dilutions of 1 : 1 (5 units) and
1 : 5 (1 unit) (7.75 ± 1.92 and 10.56 ± 1.23 mm, 5.12 ± 0.91 and
5.93 ± 1.74 mm respectively).
At baseline, we measured limb volumes of both affected
(mean value: 3463 cm3 in range 2650–4230 cm3) and healthy arms
(mean value: 2998.75 cm3 in range 2318–3830 cm3), as well as
mean oedema volume calculated as volume difference between
affected and non-affected arm (mean value: 464.25 cm3 in range
197–798 cm3). DLT resulted in a significant decrease (P < 0.05)
in the mean values of lymphoedematous limb (pretreatment:
Table 1 Tuberculin skin test diameters
Patient Healthy arm TST diameter (mm) Affected arm before decongestion
TST diameter (mm)
Affected arm after decongestion TST
diameter (mm)
5 TU 1 TU 0.5 TU 5 TU 1 TU 0.5 TU 5 TU 1 TU 0.5 TU
1 10 8 7 9 6.5 5 9 8 5
2 12.5 7 6 6 4.5 4 11.5 7 5
3 17 6 4 11 4.5 4 12 4 4
4 10 6 3 5.5 4.5 3 9 6.5 4
5 10 6 2 6 6 3 10 5 3
6 11 9 7 7 5 5 10 7 4
7 12 8 6 8.5 4 4 12 7 2
8 12 7 5 9 6 5 11 3 3
Mean ± SD 11.81 ± 2.32 7.12 ± 1.12 5.00 ± 1.85 7.75 ± 1.92 5.12 ± 0.91 4.12 ± 0.83 10.56 ± 1.23 5.93 ± 1.74 3.75 ± 1.03
Two independent examiners accomplished single measurements at each TST and the values are expressed as means of these two results.
TU – tuberculin unit.
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3463 cm3, posttreatment: 3161.625 cm3) and oedema volumes
(pretreatment: 464.25 cm3, posttreatment: 301.375 cm3), whereas
healthy limbs remained unchanged (Table 2).
It is noteworthy that TST exerted a mild volume increase
in involved arms in three cases, which was restored with an
additional 5-day cycle of DLT.
Discussion
Lymphoedema is often featured by complications such as recur-
rent erysipelas, fungal or even herpes virus infections. Lymphoede-
matous limbs are prone to develop primary or more commonly
secondary malignancies. Several attempts have been made to
identify the underlying causes. The link between lymph stasis and
disturbed immune function was first described in 1982, when
intradermal skin tests to common allergens in a patient with uni-
lateral Stewart–Treves syndrome of the right leg showed weak
reaction on the involved limb and normal skin reactions on both
arms and contralateral leg.4 In 1984, the same finding was detected
in a lymphedematous leg with classical KS.5,6 As the disease pro-
gressed and involved more limbs with KS in conjunction with
lymphoedema, it resulted concomitantly impaired immune
response on the affected extremity. Finally, each limb developed
KS and secondary lymphoedema with negatively conversed skin
tests.5,6 In DNCB-sensitized classical KS patients, the rechallenge
showed impaired immune response on involved limbs.7 Further
clinical trials involving arms with chronic lymphoedema showed a
disturbed trafficking of immune cells after DNCB rechallenge. In
their study on postmastectomy lymphoedema, Mallon et al. found
that both the afferent and efferent loops of immune response were
compromised with decreased hypersensitivity reactions.8 These
data clarified that lymph stasis directly causes immunostasis.
While trying to elucidate the permanent weakness of
cell-mediated immunity of lymphoedematous limbs, we observed
that intensive and later maintenance phases of DLT reduce the
frequency of cellulitis. This empirical body of knowledge and the
finding of a clinical report9 promoted us to conduct a clinical trial
to study the effect of decongestion on immune status of lympho-
edematous limbs in the belief that the less frequent attack of this
severe bacterial infection might be attributed to an improved
defence mechanism.
Prior and subsequent to DLT, TST was performed on involved
forearms. Repeated TST can result in boosting, because it might
evoke a recall of delayed-type hypersensitivity to mycobacterial
antigens that has waned. Singh et al. reported that the retest read-
ing after 72 h did not prove any significant change in the size of
reaction hence ruling out the boosting effect.15 In a separate study,
healthy volunteers were subjected to TST in a repeated fashion
and no significant changes of TST induration sizes were detected.
Following the completion of DLT course, we intentionally did
not retest healthy arm with PPD injections so as to exclude the
possible influences of MLD on the lymphatic circulation of
healthy arm.
Our study has revealed that cell-mediated immune response
was weaker at the two lowest dilutions of tuberculin inoculums in
the lymphoedematous arms compared with healthy ones. This
finding is quite compatible with the previous results of Mallon
et al.8
Significant increase in tuberculin reactions to 1 or 5 tuberculin
units proved that DLT had immunomodulatory effect and could
partially restore the cellular immune status of the arm with BCRL.
To our knowledge no previous study examined the effect of
DLT on lymphoedematous limbs from the cellular immunity
point of view.
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